Shopping Cart

Your shopping cart is currently empty

Milvexian (Synonyms: JNJ-70033093, BMS-986177)

Name: Milvexian
Brand: TargetMol
SKU: T39223
Price: 496 USD
Availability: InStock
Rating: 5 (10 reviews)

Catalog No. T39223 Copy Product Info

Purity: 99.91%

🥰Excellent

Milvexian (BMS-986177/JNJ-70033093) is an orally bioavailable, small-molecule, reversible, and direct antagonist of Factor XIa (FXIa). It exhibits potent inhibitory activity across species, with Ki values of 0.11 nM for human, 0.38 nM for rabbit, and 0.64 nM for dog. By targeting FXIa, Milvexian selectively inhibits the intrinsic pathway of the coagulation cascade. It demonstrates robust antithrombotic efficacy in various in vitro and in vivo models while maintaining a favorable safety profile regarding bleeding risk. It is a critical tool for investigating novel anticoagulant strategies in thrombosis and cardiovascular research.

Milvexian

Copy Product Info

🥰Excellent

Catalog No. T39223

Synonyms JNJ-70033093, BMS-986177

Cas No. 1802425-99-5

Pack Size	Price	USA Stock	Global Stock
1 mg	$496	-	In Stock
5 mg	$993	-	In Stock
10 mg	$1,490	-	In Stock
25 mg	$2,680	-	In Stock
50 mg	$3,760	-	In Stock
1 mL x 10 mM (in DMSO)	$1,370	-	In Stock

For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)

Add to Cart

Add to Quotation

Custom-made molecule. TargetMol’s expert synthesis team delivers cost-effective solutions. Contact us for inquiries. Committed to serving you.

For research use only—not for human use. No sales to individuals. Use as intended only.

Questions

Batch Information

Select Batch

Purity:99.91%

Appearance:Solid

Color:White

Resource Download

COA LCMS HNMR

Product Introduction

Bioactivity

Description	Milvexian (BMS-986177/JNJ-70033093) is an orally bioavailable, small-molecule, reversible, and direct antagonist of Factor XIa (FXIa). It exhibits potent inhibitory activity across species, with Ki values of 0.11 nM for human, 0.38 nM for rabbit, and 0.64 nM for dog. By targeting FXIa, Milvexian selectively inhibits the intrinsic pathway of the coagulation cascade. It demonstrates robust antithrombotic efficacy in various in vitro and in vivo models while maintaining a favorable safety profile regarding bleeding risk. It is a critical tool for investigating novel anticoagulant strategies in thrombosis and cardiovascular research.
In vitro	Milvexian (~10 μM) prolongs aPTT in human plasma, confirming selective blockade of the intrinsic coagulation pathway. It does not affect platelet aggregation induced by ADP or collagen, indicating that its antithrombotic effect is coagulation-specific, offering a mechanistic advantage in reducing bleeding risk [1].
In vivo	In a rabbit thrombosis model, Milvexian dose-dependently maintained carotid blood flow (32–76%) and reduced thrombus weight (15–70%) following i.v. administration. Orally dosed at 20 mg/kg, it achieved a plasma concentration of 2000 nM at 1 h, demonstrating favorable PK [1][2].
Synonyms	JNJ-70033093, BMS-986177

Chemical Properties

Molecular Weight	626.45
Formula	C₂₈H₂₃Cl₂F₂N₉O₂
Cas No.	1802425-99-5
Smiles	C(F)(F)N1C=2C=3C=C([C@H](CCC[C@@H](C)C(=O)NC2C=N1)N4C(=O)C=C(N=C4)C5=C(C=CC(Cl)=C5)N6C=C(Cl)N=N6)N=CC3

Storage & Solubility Information

Storage

Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 80 mg/mL (127.7 mM)

Solution Preparation Table

DMSO

	1mg	5mg	10mg	50mg
1 mM	1.5963 mL	7.9815 mL	15.9630 mL	79.8148 mL
5 mM	0.3193 mL	1.5963 mL	3.1926 mL	15.9630 mL
10 mM	0.1596 mL	0.7981 mL	1.5963 mL	7.9815 mL
20 mM	0.0798 mL	0.3991 mL	0.7981 mL	3.9907 mL
50 mM	0.0319 mL	0.1596 mL	0.3193 mL	1.5963 mL
100 mM	0.0160 mL	0.0798 mL	0.1596 mL	0.7981 mL

Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Citations

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc